Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Oct 25, 2023 10:17pm
143 Views
Post# 35701379

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:National Bank Comments

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:National Bank CommentsWhy do this deal now? We can only speculate but here are three guesses:

1.) The financial engineering required to produce the good results at the end of Q3 have started to reverse and they were likely to violate the $20 million cash buffer again. But why raise so much and dilute current shareholders by so much even if this was the case.

2.) The first TH-1902 patient has already seen some toxicity leading the company to be concerned about the outcome of the trial and the ability to gain cash from psrtnership deals. 

3.) They were worried that shareholders, who came very close to firing them at the last AGM, might call a special meeting to actually do it this time. By doing such a large offering well before it was necessary, they cut that possibility off at the pass. Yes that is ugly but this seems to me to be the most likely reason for the early timing and large size of the offering.

 




juniper88 wrote: My point was more like "buyer beware". They threw us under the bus (twice now), soleus (if they sold it was at a substantial loss), and Paul will have no loyalty for the next investor either. 

And what is the point of laying off all those scientists if you're going to do this? The more I think about this the less sense it makes.



mikeq113 wrote: This assumes Soleus is still around. They may have already exited given how substantial the selling was around the reverse split. 






<< Previous
Bullboard Posts
Next >>